ZKN 217
Alternative Names: ZKN-217Latest Information Update: 25 Nov 2022
At a glance
- Originator Eloxx Pharmaceuticals
- Class Antineoplastics; Macrolides; Small molecules
- Mechanism of Action Ribosomal RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Small cell lung cancer